Generon

Generon is a biopharmaceutical company headquartered in Shanghai, specializing in the development of innovative biologics for oncology and inflammatory diseases. The company leverages its proprietary Di-Kine and IT-body platforms to engineer therapeutic proteins and multi-specific antibodies. Its flagship product, Ryzneuta (efbemalenograstim alfa), is a long-acting G-CSF fusion protein that has received regulatory approval in the United States and China for chemotherapy-induced neutropenia. Beyond its commercial success, Generon maintains a clinical pipeline including F-652, a first-in-class IL-22 fusion protein being evaluated for graft-versus-host disease and acute pancreatitis. The company operates as a subsidiary of Yifan Pharmaceutical, focusing on global commercialization through strategic international partnerships.